BioGaia has today extended its global contract with Nestle Nutrition by signing
an agreement with the company’s UK infant nutrition business for the exclusive
rights to sell BioGaia’s ProTectis Baby Drops in the United Kingdom and Ireland.
Launch is planned to take place in the beginning of 2015.
Nestle Nutrition UK will market both BioGaia ProTectis Baby Drops, which is
BioGaia's biggest product, and BioGaia ProTectis Baby Drops with vitamin D. Both
products contain BioGaia's patented and well-documented probiotic strain
Lactobacillus reuteri Protectis. Today the drops are sold in 60 countries
worldwide.
“I am delighted that we after many years of preparations have been able to
conclude a contract for this large market. We have established an important key
opinion leader network in the UK and the drops are already sold in a few
hospital pharmacies. Considering Nestle Nutrition’s presence in the market and
our preparatory work I am convinced that sales will expand quickly”, says Peter
Rothschild, President, BioGaia.
Latest press releases from BioGaia
2014-06-17 BioGaia signs distribution agreement for India
2014-05-07 Annual General Meeting of BioGaia AB
2014-05-06 BioGaia AB: Interim management statement 1 January-31 March 2014
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 18 June 2014, 1:15 pm
CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
